J. García-González

Efficacy, safety and cost-effectiveness of methotrexate, adalimumab or their combination in non-infectious non-anterior uveitis: a protocol for a multicentre, randomised, parallel three arms, active-controlled, phase III open label with blinded outcome assessment study

L. Rodríguez-Rodríguez, A. López-Picado, M. Cordero-Coma, 2022, BMJ Open.

Inflammatory Relapses after Immunosuppressive Drug Discontinuation in Uveitis Patients: A Survival Analysis

L. Rodríguez-Rodríguez, E. Pato, L. Borrego-Sanz, 2019, Ocular immunology and inflammation.

New era of personalized medicine: Advanced therapy medicinal products in Europe

J. Beltrán-García, J. García-González, Sonia Marhuenda-Castillo, 2021, World Journal of Immunology.

Safety and effectiveness of bDMARDs during pregnancy in patients with rheumatic diseases: Real-world data from the BIOBADASER registry

C. Sánchez-Piedra, F. Sánchez-Alonso, R. Cáliz-Cáliz, 2023, Reumatología Clínica.

Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years

C. Sánchez-Piedra, F. Sánchez-Alonso, E. González-Dávila, 2021, Scientific Reports.

Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER

E. Pérez-Pampín, J. Gómez-Reino, C. Sánchez-Piedra, 2018, Arthritis Research & Therapy.

Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab

E. Pérez-Blázquez, C. Navarro-Perea, J. García-González, 2019, Indian journal of ophthalmology.

Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis.

C. Sánchez-Piedra, C. Bohórquez, C. Rodríguez-Lozano, 2023, European journal of clinical investigation.